Loading
Obesity & Overweight / Probiotics (Natural product) / Digestive Disorders · Interventional Study
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned interventional study (not yet reported) evaluating whether probiotics reduce gastrointestinal side effects during GLP-1 receptor agonist dose escalation in obese patients. The registry record presents the rationale and study protocol only; no efficacy or safety data are available in this source.
Interventional, Randomized, Parallel, Double masking, Prevention purpose. Obesity &Amp; Overweight, Digestive Disorders; age from 18 Years; to 75 Years. Intervention: Probiotics. Compared with: Placebo — Placebo Comparator. n = 50. 1 site: France.
This is a planned interventional study (not yet reported) evaluating whether probiotics reduce gastrointestinal side effects during GLP-1 receptor agonist dose escalation in obese patients. The registry record presents the rationale and study protocol only; no efficacy or safety data are available in this source.
This is a registry record with no posted results; no efficacy or safety data are available. Primary outcome is digestive quality of life (surrogate), not hard clinical endpoints such as treatment discontinuation rate or weight loss.
Clinicians should not yet draw clinical conclusions from this registry record, as results are not posted. The study aims to address a real clinical problem—GI tolerability of GLP-1 RAs during dose escalation—but efficacy data will be needed before probiotics can be recommended as adjunctive therapy for this indication.
This is a clinical trial registry record with no posted results; it describes a planned interventional study testing probiotics to mitigate GI side effects of GLP-1 RAs in obesity, with estimated enrollment of 50 participants and a surrogate primary outcome (digestive quality of life).
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should not yet draw clinical conclusions from this registry record, as results are not posted. The study aims to address a real clinical problem—GI tolerability of GLP-1 RAs during dose escalation—but efficacy data will be needed before probiotics can be recommended as adjunctive therapy for this indication.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07213323). This is a study registration, not published results. Lead sponsor: Hospices Civils de Lyon. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 50 participants (ESTIMATED). Conditions: Obesity & Overweight, Digestive Disorders. Interventions: DIETARY_SUPPLEMENT: Probiotics (Natural product); OTHER: Placebo. Primary outcome measures: Assessment of the Limitation of the impairment in digestive quality of life during the dose escalation of GLP1-RA (semaglutide or tirzepatide) , Every 5 weeks. Brief summary: Obesity is a prevalent chronic disease affecting 17% of the French population. Treatment involves multiple factors, with pharmacotherapy playing an increasingly important role. GLP-1 receptor agonists (GLP1 RAs) are considered revolutionary in obesity treatment, with three approved molecules available in France: liraglutide, semaglutide, and tirzepatide. These treatments, combined with a healthy lifestyle, induce significant weight loss: 9% with liraglutide, 15% with semaglutide, and 20% with tirzepatide. The most common adverse events (AEs) associated with GLP-1 RAs are gastrointestinal (GI) disorders, including nausea, vomiting, diarrhea, and abdominal pain. These AEs are dose-dependent and often decline over time. In phase 3 trials, semaglutide 2.4 mg showed higher rates of GI AEs compared to placebo, but most were mild to moderate and transient. GI AEs led to dose reduction or temporary treatment interruption in 12.5% of participants, with few permanent discontinuations. Probiotics, are live microorganisms that benefit the host by improving gut microflora. Probiotics has been clinically proven to benefit gastrointestinal health. Probiotics may reduces symptoms of irritable bowel syndrome (IBS), improves gut barrier function, reduces inflammation, and decreases the incidence of C. difficile infection (CDI) in patients taking antibiotics. Probiotics is therefore theorized to potentially reduce GI side effects associated with GLP-1 RA treatment for obesity. Hypothesis Probiotics will prevent and limit the digestive disorders induced by GLP-1 R agonists, particularly during the dose escalation period. This would allow better digestive tolerance of the treatments, limiting the number of definitive treatment interruptions, facilitating compliance and dose escalation with a larger number of subjects at full dose and therefore with better systemic exposure to the compounds, a key factor in their effects on weight loss.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.